Log in

Aimmune Therapeutics Stock Price, Forecast & Analysis (NASDAQ:AIMT)

$26.95
+0.28 (+1.05 %)
(As of 11/19/2019 08:00 AM ET)
Today's Range
$26.38
Now: $26.95
$27.23
50-Day Range
$20.53
MA: $25.93
$29.58
52-Week Range
$16.95
Now: $26.95
$31.83
Volume557,500 shs
Average Volume722,072 shs
Market Capitalization$1.69 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.03
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AIMT
CUSIPN/A
Phone650-614-5220

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.09 per share

Profitability

Net Income$-210,750,000.00

Miscellaneous

Employees228
Market Cap$1.69 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive AIMT News and Ratings via Email

Sign-up to receive the latest news and ratings for AIMT and its competitors with MarketBeat's FREE daily newsletter.


Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions

What is Aimmune Therapeutics' stock symbol?

Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."

How were Aimmune Therapeutics' earnings last quarter?

Aimmune Therapeutics Inc (NASDAQ:AIMT) announced its quarterly earnings data on Wednesday, November, 6th. The biotechnology company reported ($1.03) EPS for the quarter, hitting the Zacks' consensus estimate of ($1.03). During the same quarter in the prior year, the business posted ($0.89) earnings per share. View Aimmune Therapeutics' Earnings History.

When is Aimmune Therapeutics' next earnings date?

Aimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Aimmune Therapeutics.

What price target have analysts set for AIMT?

8 brokerages have issued twelve-month price targets for Aimmune Therapeutics' shares. Their forecasts range from $27.00 to $79.00. On average, they anticipate Aimmune Therapeutics' stock price to reach $45.75 in the next twelve months. This suggests a possible upside of 69.8% from the stock's current price. View Analyst Price Targets for Aimmune Therapeutics.

What is the consensus analysts' recommendation for Aimmune Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aimmune Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aimmune Therapeutics.

What are Wall Street analysts saying about Aimmune Therapeutics stock?

Here are some recent quotes from research analysts about Aimmune Therapeutics stock:
  • 1. According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (11/7/2019)
  • 2. Stifel Nicolaus analysts commented, "We continue to expect the focus of the Adcom to be on safety – risk of anaphylaxis and use of epinephrine – which is not new" news and we think also around the long-term use/safety of AR101 in patients (i.e. EoE). We think this should provide some relief for shares today as the investors’ worst case" scenario in terms of the panel may be off the table as the agency struck a relatively positive tone in the docs, in our view. With the stock continuing to move up ahead of the Adcom, we think the risk/reward at these levels is less favorable once Palforzia is approved given the commercial/logistical challenges we feel lay ahead, which is core to our thesis, and the Adcom isn’t completely devoid of risk." (9/11/2019)

Has Aimmune Therapeutics been receiving favorable news coverage?

News stories about AIMT stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Aimmune Therapeutics earned a media sentiment score of -3.9 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Aimmune Therapeutics.

Are investors shorting Aimmune Therapeutics?

Aimmune Therapeutics saw a drop in short interest in the month of October. As of October 15th, there was short interest totalling 11,420,000 shares, a drop of 20.9% from the September 15th total of 14,430,000 shares. Based on an average daily trading volume, of 1,020,000 shares, the short-interest ratio is currently 11.2 days. Approximately 29.5% of the company's stock are short sold. View Aimmune Therapeutics' Current Options Chain.

Who are some of Aimmune Therapeutics' key competitors?

What other stocks do shareholders of Aimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aimmune Therapeutics investors own include Hawkins (HWKN), Alibaba Group (BABA), CA (CA), Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Micron Technology (MU), AbbVie (ABBV), BlackRock (BLK), Amarin (AMRN) and Endologix (ELGX).

Who are Aimmune Therapeutics' key executives?

Aimmune Therapeutics' management team includes the folowing people:
  • Dr. Jayson Donald Alexander Dallas, Pres, CEO & Director (Age 51)
  • Mr. Eric H. Bjerkholt, Chief Financial Officer (Age 59)
  • Mr. Douglas T. Sheehy, Gen. Counsel & Sec. (Age 52)
  • Dr. Stephen George Dilly, Special Advisor (Age 59)
  • Dr. Daniel C. Adelman, Chief Medical Officer (Age 62)

When did Aimmune Therapeutics IPO?

(AIMT) raised $124 million in an initial public offering on Thursday, August 6th 2015. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO.

Who are Aimmune Therapeutics' major shareholders?

Aimmune Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (1.20%), Emerald Advisers LLC (0.97%), Emerald Mutual Fund Advisers Trust (0.94%), Massachusetts Financial Services Co. MA (0.86%), GW&K Investment Management LLC (0.44%) and State of New Jersey Common Pension Fund D (0.19%). Company insiders that own Aimmune Therapeutics stock include Bakker Juliet Tammenoms, Daniel C Md Adelman, Douglas T Sheehy, Eric Bjerkholt, Jayson Donald Alexander Dallas, Kathryn E Falberg, Mary M Rozenman, Patrick G Enright, Stephen George Dilly and Susan E Barrowcliffe. View Institutional Ownership Trends for Aimmune Therapeutics.

Which institutional investors are selling Aimmune Therapeutics stock?

AIMT stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust and Mackay Shields LLC. View Insider Buying and Selling for Aimmune Therapeutics.

Which institutional investors are buying Aimmune Therapeutics stock?

AIMT stock was purchased by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Massachusetts Financial Services Co. MA, Rice Hall James & Associates LLC, GW&K Investment Management LLC, Lisanti Capital Growth LLC, California Public Employees Retirement System, Brinker Capital Inc. and Envestnet Asset Management Inc.. Company insiders that have bought Aimmune Therapeutics stock in the last two years include Bakker Juliet Tammenoms, Eric Bjerkholt, Jayson Donald Alexander Dallas, Kathryn E Falberg and Patrick G Enright. View Insider Buying and Selling for Aimmune Therapeutics.

How do I buy shares of Aimmune Therapeutics?

Shares of AIMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aimmune Therapeutics' stock price today?

One share of AIMT stock can currently be purchased for approximately $26.95.

How big of a company is Aimmune Therapeutics?

Aimmune Therapeutics has a market capitalization of $1.69 billion. The biotechnology company earns $-210,750,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis. Aimmune Therapeutics employs 228 workers across the globe.View Additional Information About Aimmune Therapeutics.

What is Aimmune Therapeutics' official website?

The official website for Aimmune Therapeutics is http://www.aimmune.com/.

How can I contact Aimmune Therapeutics?

Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected]


MarketBeat Community Rating for Aimmune Therapeutics (NASDAQ AIMT)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  399 (Vote Outperform)
Underperform Votes:  278 (Vote Underperform)
Total Votes:  677
MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote "Outperform" if you believe AIMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AIMT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel